ADC Therapeutics SA (ADCT)

The investment case for ADC Therapeutics is currently broken by a perfect storm of deteriorating fundamentals and severe market skepticism. The company is bleeding cash, with negative free cash flow and operating margins, while simultaneously cutting staff to fund its core asset, ZYNLONTA. The recent news of patient deaths in a blood cancer trial has likely triggered the heavy put buying seen in the options chain, creating a self-reinforcing cycle of pessimism. While the analyst consensus remains technically 'Buy' with a mean target of $5.00, this appears to be a lagging indicator detached from the reality of the balance sheet. The stock has lost over 90% of its value over the last five years, and despite a brief recovery in 2024, it is now facing another year of decline. The statistical forecasting model, which predicts a nearly 10% drop over the next 45 days, aligns with the bearish options flow, though its low reliability suggests the market is simply pricing in extreme uncertainty rather than a precise mathematical outcome. There is no dividend to provide a floor, and the negative book value indicates the market sees the assets as liabilities. Until there is concrete evidence that the ZYNLONTA trials will succeed without further safety issues, and until the company demonstrates a path to profitability or a massive cash infusion, the risk/reward profile remains heavily skewed toward further capital erosion. The current price action reflects a deep loss of confidence, making this a dangerous environment for both short-term traders and long-term holders.